Ignite Creation Date:
2024-05-11 @ 8:30 AM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06405464
Status:
RECRUITING
Last Update Posted:
2024-05-08
First Post:
2024-04-15
Brief Title:
Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort StudyUptake Outcome and Risk Factors for Treatment Failures
Sponsor:
University of Zurich
Organization:
University of Zurich
Study Overview
Official Title:
Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study Uptake Outcome and Risk Factors for Treatment Failures in a Real-world Setting
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to characterize Swiss HIV Cohort Study participants initiating the CABRPV LA regimen assess adherence to Swiss label indications and describe treatment outcomes in this large multicentre heterogeneous high-income setting Moreover the study aims to assess virological immunological demographic clinical and behavioural factors associated with viral failure under CABRPV LA regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 222485 | OTHER_GRANT | ViiV Healthcare | None |